Tuesday, March 09, 2021 4:16:57 PM
Siegel predicted the at-home therapeutic, which could hit the U.S. market in four to five months, could be enough to turn the pandemic on its head and prove to be the "holy grail" of COVID-19 treatment.
On Sunday's "Fox & Friends Weekend," Siegel said, "It may be the holy grail on this because it was just studied in phase two trials and it literally stopped the virus in its tracks. And there wasn't any virus found in the patients that were studied."
First-stage testing on the drug, which is from Merck and Ridgeback Biotherapeutics, showed "promising signs of effectiveness in reducing the virus in patients," the outlet noted.
The drug, according to Fox, would be used at home as a five-day treatment, not unlike how Tamiflu is prescribed to combat the effects of influenza.
"This might be the future once the vaccine really gets control over the pandemic and we just start seeing isolated cases," he said. "By then, this drug might be ready and this might be the drug for over the next several months."
Siegel has also predicted that the United States will be "free of the coronavirus pandemic by the summer."
"This is the very first pill that we have that's something that we might be able to use in our armamentarium against COVID as a therapeutic," he added.
On Saturday, Mint reported that the antiviral drug causes quick reduction in the virus.
In a statement from the companies, William Fischer, associate professor of medicine at the University of North Carolina School of Medicine, said, "The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising and if supported by additional studies, could have important public health implications."
"At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data," Wendy Painter, chief medical officer of Ridgeback, added in the statement.
https://www.theblaze.com/news/new-medication-treat-covid-holy-grail?utm_source=theblaze-dailyAM&utm_medium=email&utm_campaign=Daily-Newsletter__AM%202021-03-09&utm_term=ACTIVE%20LIST%20-%20TheBlaze%20Daily%20AM
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM